Cash-Tight MAP Could Win With Inhaled Migraine Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s switch to backup CGRP after liver-enzyme trouble could provide an edge to MAP Pharmaceuticals.
You may also be interested in...
Merck Delays Migraine Drug Filing; Q1 Sales Fall Short of Analyst Expectations
Telcagepant approval, next anticipated opportunity in pipeline, at standstill; analysts look to Schering-Plough deal to bolster Merck sales.
NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
Deal terms may show pharma’s faith that Afresa can beat the stigma of Pfizer’s fizzled Exubera.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf